Improved Efficacy of Topical Latanoprost 0.005% Demonstrated by Corneal Biomechanical Correcting Modified Goldmann Prism

Nathan Radcliffe,1 John Berdahl,2 Mitchel Ibach,2 Justin Schweitzer,2 Jason Levine,3 Sean McCafferty3 1New York Eye Surgery Center, New York, NY, USA; 2Vance Thompson Vision, Sioux Falls, SD, USA; 3Arizona Eye Consultants, Tucson, AZ, USACorrespondence: Sean McCaffertyArizona Eye Consultants, 6422 E...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Radcliffe N, Berdahl J, Ibach M, Schweitzer J, Levine J, McCafferty S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	glaucoma prostaglandins iop tonometer corneal biomechanics timolol latanoprost Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/5f93871192704458a2cd480903ab038d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5f93871192704458a2cd480903ab038d
record_format	dspace
spelling	oai:doaj.org-article:5f93871192704458a2cd480903ab038d2021-12-02T10:08:47ZImproved Efficacy of Topical Latanoprost 0.005% Demonstrated by Corneal Biomechanical Correcting Modified Goldmann Prism1177-5483https://doaj.org/article/5f93871192704458a2cd480903ab038d2020-08-01T00:00:00Zhttps://www.dovepress.com/improved-efficacy-of-topical-latanoprost-0005-demonstrated-by-corneal--peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Nathan Radcliffe,1 John Berdahl,2 Mitchel Ibach,2 Justin Schweitzer,2 Jason Levine,3 Sean McCafferty3 1New York Eye Surgery Center, New York, NY, USA; 2Vance Thompson Vision, Sioux Falls, SD, USA; 3Arizona Eye Consultants, Tucson, AZ, USACorrespondence: Sean McCaffertyArizona Eye Consultants, 6422 E. Speedway Blvd, Tucson, AZ 85710, USATel +1 (520) 327-3487Email SJMccafferty66@hotmail.comPurpose: To evaluate intraocular pressure (IOP) reduction measured by a Goldmann applanation tonometer (GAT) prism and a modified surface Goldmann (CATS) prism with the institution of a topical prostaglandin analog (PGA) or alternatively a topical beta blocker.Design: Prospective, open-label, randomized, controlled, and reference device comparison.Methods: Thirty-six (36) treatment naïve glaucoma patients (72 eyes) were randomized equally to treatment with latanoprost 0.005% or timolol maleate 0.5%. Each patient underwent IOP measurement with standard GAT and CATS prisms before and at 1, 3, and 6 months of treatment. Central corneal thickness (CCT) and corneal hysteresis (CH) were also measured. Medication response was defined as a 20% reduction in IOP from baseline.Results: The CATS prism demonstrated the IOP reduction with topical latanoprost at a mean of 1.9 mmHg lower than the IOP measured with GAT (p=0.01). The CATS and GAT prisms detected no difference in IOP reduction with timolol (p=0.23). The number of latanoprost treatment non-responders was reduced from 36.1% measured with GAT to 13.8% when measured with the CATS prism (p=0.005). Timolol indicated no difference in the treatment non-response rate at 22.2% (p=0.999). CH increased significantly with latanoprost treatment by an average of 0.55 mmHg (p=0.014) and remained unchanged with timolol at − 0.014 mmHg (p=0.68).Discussion: IOP reduction and responder rates were increased when measured with a CATS prism in patients using latanoprost and not with timolol use. Latanoprost-induced alterations in corneal biomechanics may dampen the actual IOP reduction measured with a standard GAT prism.Clinical Trial Registration: ClinicalTrials.gov NCT04178863.Keywords: glaucoma, prostaglandins, IOP, tonometer, corneal biomechanics, timolol, latanoprostRadcliffe NBerdahl JIbach MSchweitzer JLevine JMcCafferty SDove Medical Pressarticleglaucomaprostaglandinsioptonometercorneal biomechanicstimolollatanoprostOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 14, Pp 2245-2253 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	glaucoma prostaglandins iop tonometer corneal biomechanics timolol latanoprost Ophthalmology RE1-994
spellingShingle	glaucoma prostaglandins iop tonometer corneal biomechanics timolol latanoprost Ophthalmology RE1-994 Radcliffe N Berdahl J Ibach M Schweitzer J Levine J McCafferty S Improved Efficacy of Topical Latanoprost 0.005% Demonstrated by Corneal Biomechanical Correcting Modified Goldmann Prism
description	Nathan Radcliffe,1 John Berdahl,2 Mitchel Ibach,2 Justin Schweitzer,2 Jason Levine,3 Sean McCafferty3 1New York Eye Surgery Center, New York, NY, USA; 2Vance Thompson Vision, Sioux Falls, SD, USA; 3Arizona Eye Consultants, Tucson, AZ, USACorrespondence: Sean McCaffertyArizona Eye Consultants, 6422 E. Speedway Blvd, Tucson, AZ 85710, USATel +1 (520) 327-3487Email SJMccafferty66@hotmail.comPurpose: To evaluate intraocular pressure (IOP) reduction measured by a Goldmann applanation tonometer (GAT) prism and a modified surface Goldmann (CATS) prism with the institution of a topical prostaglandin analog (PGA) or alternatively a topical beta blocker.Design: Prospective, open-label, randomized, controlled, and reference device comparison.Methods: Thirty-six (36) treatment naïve glaucoma patients (72 eyes) were randomized equally to treatment with latanoprost 0.005% or timolol maleate 0.5%. Each patient underwent IOP measurement with standard GAT and CATS prisms before and at 1, 3, and 6 months of treatment. Central corneal thickness (CCT) and corneal hysteresis (CH) were also measured. Medication response was defined as a 20% reduction in IOP from baseline.Results: The CATS prism demonstrated the IOP reduction with topical latanoprost at a mean of 1.9 mmHg lower than the IOP measured with GAT (p=0.01). The CATS and GAT prisms detected no difference in IOP reduction with timolol (p=0.23). The number of latanoprost treatment non-responders was reduced from 36.1% measured with GAT to 13.8% when measured with the CATS prism (p=0.005). Timolol indicated no difference in the treatment non-response rate at 22.2% (p=0.999). CH increased significantly with latanoprost treatment by an average of 0.55 mmHg (p=0.014) and remained unchanged with timolol at − 0.014 mmHg (p=0.68).Discussion: IOP reduction and responder rates were increased when measured with a CATS prism in patients using latanoprost and not with timolol use. Latanoprost-induced alterations in corneal biomechanics may dampen the actual IOP reduction measured with a standard GAT prism.Clinical Trial Registration: ClinicalTrials.gov NCT04178863.Keywords: glaucoma, prostaglandins, IOP, tonometer, corneal biomechanics, timolol, latanoprost
format	article
author	Radcliffe N Berdahl J Ibach M Schweitzer J Levine J McCafferty S
author_facet	Radcliffe N Berdahl J Ibach M Schweitzer J Levine J McCafferty S
author_sort	Radcliffe N
title	Improved Efficacy of Topical Latanoprost 0.005% Demonstrated by Corneal Biomechanical Correcting Modified Goldmann Prism
title_short	Improved Efficacy of Topical Latanoprost 0.005% Demonstrated by Corneal Biomechanical Correcting Modified Goldmann Prism
title_full	Improved Efficacy of Topical Latanoprost 0.005% Demonstrated by Corneal Biomechanical Correcting Modified Goldmann Prism
title_fullStr	Improved Efficacy of Topical Latanoprost 0.005% Demonstrated by Corneal Biomechanical Correcting Modified Goldmann Prism
title_full_unstemmed	Improved Efficacy of Topical Latanoprost 0.005% Demonstrated by Corneal Biomechanical Correcting Modified Goldmann Prism
title_sort	improved efficacy of topical latanoprost 0.005% demonstrated by corneal biomechanical correcting modified goldmann prism
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/5f93871192704458a2cd480903ab038d
work_keys_str_mv	AT radcliffen improvedefficacyoftopicallatanoprost0005demonstratedbycornealbiomechanicalcorrectingmodifiedgoldmannprism AT berdahlj improvedefficacyoftopicallatanoprost0005demonstratedbycornealbiomechanicalcorrectingmodifiedgoldmannprism AT ibachm improvedefficacyoftopicallatanoprost0005demonstratedbycornealbiomechanicalcorrectingmodifiedgoldmannprism AT schweitzerj improvedefficacyoftopicallatanoprost0005demonstratedbycornealbiomechanicalcorrectingmodifiedgoldmannprism AT levinej improvedefficacyoftopicallatanoprost0005demonstratedbycornealbiomechanicalcorrectingmodifiedgoldmannprism AT mccaffertys improvedefficacyoftopicallatanoprost0005demonstratedbycornealbiomechanicalcorrectingmodifiedgoldmannprism
_version_	1718397581889896448

Improved Efficacy of Topical Latanoprost 0.005% Demonstrated by Corneal Biomechanical Correcting Modified Goldmann Prism

Ejemplares similares